Ultragenyx Releases 2025 Impact Report, Highlights ESG Progress

Ultragenyx Pharmaceutical Inc. released its 2025 Impact Report, detailing significant progress in its corporate responsibility efforts for patients with rare diseases. The report highlights advancements in five investigational therapies, a substantial investment of 62% of operating expenses in R&D, and expanded access to approved treatments for over 700 patients in 50 countries. The company also emphasized its commitment to ESG, including $3.3 million in charitable donations and achieving nearly 100% renewable electricity for key facilities.